The global amyloidosis therapeutics market size is calculated at USD 3.18 billion in 2025 and is forecasted to reach around USD 6.45 billion by 2034, accelerating at a CAGR of 8.18% from 2025 to 2034. The North America market size surpassed USD 1.38 billion in 2024 and is expanding at a CAGR of 8.28% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Amyloidosis Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Amyloidosis Therapeutics Market, by Treatment
8.1.1. Chemotherapyok
8.1.1.1. Market Revenue and Forecast
8.1.2. Immunosuppressive Drugs
8.1.2.1. Market Revenue and Forecast
8.1.3. Transplantation
8.1.3.1. Market Revenue and Forecast
8.1.4. Supportive Care
8.1.4.1. Market Revenue and Forecast
8.1.5. Surgery
8.1.5.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Amyloidosis Therapeutics Market, by End User
9.1.1. Hospitals & Clinics
9.1.1.1. Market Revenue and Forecast
9.1.2. Ambulatory Surgical Centers
9.1.2.1. Market Revenue and Forecast
9.1.3. Home Care Settings
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment
10.1.2. Market Revenue and Forecast, by End User
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment
10.1.3.2. Market Revenue and Forecast, by End User
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment
10.1.4.2. Market Revenue and Forecast, by End User
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment
10.2.2. Market Revenue and Forecast, by End User
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment
10.2.3.2. Market Revenue and Forecast, by End User
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment
10.2.4.2. Market Revenue and Forecast, by End User
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment
10.2.5.2. Market Revenue and Forecast, by End User
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment
10.2.6.2. Market Revenue and Forecast, by End User
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment
10.3.2. Market Revenue and Forecast, by End User
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment
10.3.3.2. Market Revenue and Forecast, by End User
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment
10.3.4.2. Market Revenue and Forecast, by End User
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment
10.3.5.2. Market Revenue and Forecast, by End User
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment
10.3.6.2. Market Revenue and Forecast, by End User
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment
10.4.2. Market Revenue and Forecast, by End User
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment
10.4.3.2. Market Revenue and Forecast, by End User
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment
10.4.4.2. Market Revenue and Forecast, by End User
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment
10.4.5.2. Market Revenue and Forecast, by End User
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment
10.4.6.2. Market Revenue and Forecast, by End User
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment
10.5.2. Market Revenue and Forecast, by End User
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment
10.5.3.2. Market Revenue and Forecast, by End User
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment
10.5.4.2. Market Revenue and Forecast, by End User
11.1. Alnylam Pharmaceuticals, Inc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Amgen Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bristol-Myers Squibb Company
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. F. Hoffmann-La Roche Ltd
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. GSK plc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Takeda Pharmaceutical Company Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sanofi
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Pfizer Inc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Johnson & Johnson Services, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Merck KGaA
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample